Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 6, 2018, Pages 1089-1098

  Bertling, A ^a   Fender, A C ^a,b   Schungel L ^a   Rumpf, M ^a   Mergemeier, K ^a   Geissler G ^a   Sibrowski, W ^a   Kelsch, R ^a   Waltenberger, J ^a   Jakubowski, J A ^c   Kehrel, B E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; P2Y12 antagonist; platelet; reversibility; thienopyridine

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; FIBRINOGEN; PADGEM PROTEIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DONOR THROMBOCYTE; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GEL FILTERED THROMBOCYTE; HAPLOTYPE; HLA TYPING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOCYTE TRANSFUSION; ADVERSE EVENT; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL DECISION MAKING; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PATIENT SELECTION; RISK FACTOR; THROMBOCYTE AGGREGATION;

BLOOD PLATELETS; CLINICAL DECISION-MAKING; CLOPIDOGREL; FEMALE; HUMANS; MALE; PATIENT SELECTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET TRANSFUSION; PLATELET-RICH PLASMA; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; TICAGRELOR;

EID: 85045847289     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14014     Document Type: Article

References (26)

1. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Eur Heart J 2014; 35: 2541–619.
2. Bonaca MP, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 373: 1274–5.
3. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Plato Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; Triton-TIMI Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
5. Campbell PG, Yadla S, Sen AN, Jallo J, Jabbour P. Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage. World Neurosurg 2011; 76: 100–4.
6. Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. Thromb Haemost 2010; 103: 535–44.
7. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015; 372: 196–7.
8. Maillard J, Cartier Faessler V, Fontana P, Bonhomme F. Lack of effect of platelet transfusions and desmopressin on intracranial bleeding in a patient receiving ticagrelor. A A Case Rep 2015; 4: 169–71.
9. Bertling A, Mergemeier K, Geissler GG, Sibrowski W, Kelsch R, Waltenberger J, Jakubowski J, Kehrel BE. Platelet transfusion might be a potent antidote for thienopyridines, but not for ticagrelor. J Thromb Haemostasis 2015; 13: 514.
10. Bertling A, Mergemeier K, Geissler GG, Sibrowski W, Kelsch R, Waltenberger J, Jakubowski J, Kehrel BE, Reversibility of platelet P2Y12 ADP receptor inhibition by platelet transfusion - an ex vivo comparison of prasugrel, clopidogrel and ticagrelor, Haemostaseologie 2015; 34: PO19–12 (Abstract).
11. Bonhomme F, Bonvini R, Reny JL, Poncet A, Fontana P. Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study. Platelets 2015; 26: 324–30.
12. Hobl EL, Derhaschnig U, Firbas C, Schoergenhofer C, Schwameis M, Jilma B. Reversal strategy in antagonizing the p2y12 -inhibitor ticagrelor. Eur J Clin Invest 2013; 43: 1258–61.
13. Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, Gouin-Thibault I, Samama CM, Bachelot-Loza C, Godier A. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 2016; 33: 361–7.
14. O'Connor SA, Amour J, Mercadier A, Martin R, Kerneis M, Abtan J, Brugier D, Silvain J, Barthelemy O, Leprince P, Montalescot G, Collet JP; ACTION Study Group. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of p2y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the aptitude study, Circ Cardiovasc Interv 2015; 8: e002786.
15. Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014; 34: 1077–90.
16. Kehrel BE, Brodde M. State of the art in platelet function testing. Transfus Med Hemother 2013; 40: 73–86.
17. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469–78.
18. Bertling A, Niemann S, Uekotter A, Fegeler W, Lass-Florl C, von Eiff C, Kehrel BE. Candida albicans and its metabolite gliotoxin inhibit platelet function via interaction with thiols. Thromb Haemost 2010; 104: 270–8.
19. Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet p-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20: 250–9.
20. Kelsch R, Binder TM, Elsner HA, Eiermann TH, Sibrowski W. An HLA-DR11/Dq3 haplotype with a drb1*0301 sequence motif in the third hypervariable region of the HLA-DR beta-1 chain: molecular and serological analysis of its generation in a european caucasian family. Tissue Antigens 2009; 74: 330–5.
21. Hughes DL, Evans G, Metcalfe P, Goodall AH, Williamson LM. Tracking and characterisation of transfused platelets by two colour, whole blood flow cytometry. Br J Haematol 2005; 130: 791–4.
22. Arya RC, Wander G, Gupta P. Blood component therapy: which, when and how much. J Anaesthesiol Clin Pharmacol 2011; 27: 278–84.
23. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. Cytochrome p450 3a inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735–41.
24. Cunningham MR, Nisar SP, Mundell SJ. Molecular mechanisms of platelet P2Y12 receptor regulation. Biochem Soc Trans 2013; 41: 225–30.
25. Kappelmayer J, Nagy B Jr, Miszti-Blasius K, Hevessy Z, Setiadi H. The emerging value of P-selectin as a disease marker. Clin Chem Lab Med 2004; 42: 475–86.
26. Buchanan A, Newton P, Pehrsson S, Inghardt T, Antonsson T, Svensson P, Sjogren T, Oster L, Janefeldt A, Sandinge AS, Keyes F, Austin M, Spooner J, Gennemark P, Penney M, Howells G, Vaughan T, Nylander S. Structural and functional characterization of a specific antidote for ticagrelor. Blood 2015; 125: 3484–90.